Richter transformation
When slow CLL suddenly turns into an aggressive lymphoma. Rare, hard to treat, and the focus of new immunotherapy trials.
Occurs in 2-10% of CLL, usually as clonally related diffuse large B-cell lymphoma; median survival historically under a year. Chemoimmunotherapy is poor; PD-1 blockade with BTK inhibition (zanubrutinib-tislelizumab RT1 trial, ORR ~58%), pirtobrutinib, venetoclax-based combinations, CD20×CD3 bispecifics (epcoritamab, glofitamab), and CAR-T show activity. Allogeneic transplant for responders.
Pages like this
not linked directly; found by shared links- TrialSTARGLO
Shares Glofitamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
Shares Glofitamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- TrialBRUIN CLL-321
- TrialALPINE
- TrialCaDAnCe-304
- TermLymphoma (tissue type)
Shares Glofitamab, T-cell engagers (bispecific), Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- PairingCaution: chemoimmunotherapy in del(17p)/TP53 CLL
- PairingCaution: ibrutinib in patients with cardiac risk